These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 12943471)

  • 1. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 3. Monitoring and assessing vaccine safety: a European perspective.
    Lopalco PL; Johansen K; Ciancio B; De Carvalho Gomes H; Kramarz P; Giesecke J
    Expert Rev Vaccines; 2010 Apr; 9(4):371-80. PubMed ID: 20370548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Methods for drug safety monitoring: yesterday, today, tomorrow].
    Nazimkin KE; Ovchinnikova EA; Zhuravleva MV
    Antibiot Khimioter; 2007; 52(7-8):41-52. PubMed ID: 18986024
    [No Abstract]   [Full Text] [Related]  

  • 5. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 7. Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?
    Aagaard L; Soendergaard B; Stenver DI; Hansen EH
    Br J Clin Pharmacol; 2008 Mar; 65(3):364-76. PubMed ID: 17961195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cutaneous drug reactions. A special challenge for dermatologists].
    Ständer S; Mockenhaupt M
    Hautarzt; 2014 May; 65(5):396. PubMed ID: 24820796
    [No Abstract]   [Full Text] [Related]  

  • 10. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
    Becquemont L
    Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quantification of drug risks in practice.
    Lee D; Bergman U
    WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852
    [No Abstract]   [Full Text] [Related]  

  • 14. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 16. Primum non nocere: adverse drug events must be taken seriously.
    Gurwitz D; McLeod HL
    Pharmacogenomics; 2007 Apr; 8(4):311-4. PubMed ID: 17391068
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.
    Awada Z; Zgheib NK
    Pharmacogenomics; 2014 Apr; 15(6):845-56. PubMed ID: 24897290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 19. Active surveillance for adverse events following immunization.
    Crawford NW; Clothier H; Hodgson K; Selvaraj G; Easton ML; Buttery JP
    Expert Rev Vaccines; 2014 Feb; 13(2):265-76. PubMed ID: 24350637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Farmacovigilance: the way towards a safer drug use].
    Dobrić S
    Vojnosanit Pregl; 2007 Apr; 64(4):229-30. PubMed ID: 17580530
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.